Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631692 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2022007753 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiological Characteristics and Outcome of Myocarditis and Pericarditis Temporally Associated With BNT162b2 COVID-19 Vaccine in Adolescents: Korean National Surveillance.
J Korean Med Sci
December 2024
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Background: This study aimed to investigate the epidemiological characteristics and outcomes of myocarditis/pericarditis after BNT162b2 vaccination in Korean adolescents.
Methods: This was a retrospective cohort analysis of adolescents aged 12-19 years old diagnosed with myocarditis/pericarditis within 42 days of BNT162b2 mRNA vaccination. All reported cases were investigated by city or government epidemiologists and the diagnostic certainty and causality was determined by the Korea Disease Control and Prevention Agency's Adverse Event Following Immunization Expert Advisory Committee according to the modified version of Brighton Collaboration Myocarditis/Pericarditis Working group's case definitions.
Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
Vaccine
December 2024
Optum Epidemiology, Boston, MA, USA.
Background: Limited data exists regarding the safety of the COVID-19 2023-2024 vaccine formulations and whether the safety profiles differ from the original formulations. We evaluated the association between the BNT162b2 XBB COVID-19 vaccine and the risk of 20 pre-specified adverse events of special interest (AESIs).
Methods: We identified commercially-insured individuals in the US age ≥ 6 months who received the BNT162b2 XBB COVID-19 vaccine between September 11, 2023 and January 15, 2024 within the Optum pre-adjudicated database.
Age- and sex-stratified risks of myocarditis and pericarditis attributable to COVID-19 vaccination: A systematic review and meta-analysis.
Epidemiol Rev
December 2024
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
While COVID-19 vaccines are generally very safe, the risks of myocarditis and pericarditis has been established following mRNA vaccines, with the highest risk in young males. Most systematic reviews and meta-analyses of the risk of myocarditis or pericarditis have included passive surveillance data, which is subject to reporting errors. Accurate measures of age-, sex-, vaccine dose-, and vaccine type-specific risks are crucial for assessment of the benefits and risks of the vaccination.
View Article and Find Full Text PDFAntibody Response Following COVID-19 Vaccination in Malaysian Cancer Patients and Healthy Individuals.
Cureus
November 2024
Faculty of Medicine, Universiti Malaya, Kuala Lumpur, MYS.
Introduction: There is a lack of real-world evidence on direct comparisons between COVID-19 vaccines in multiethnic low- and middle-income settings. Cancer patients have an impaired vaccine response due to the disease itself or the effects of treatment. Hence, identifying the best vaccine to use for cancer patients is important.
View Article and Find Full Text PDFmRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study.
Lancet Reg Health Am
December 2024
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Background: The Canadian National Vaccine Safety Network conducted active safety surveillance for COVID-19 vaccines. This study aimed to characterize the short-to-medium term safety of mRNA COVID-19 vaccines across the pediatric age spectrum.
Methods: In this cohort study, vaccinated and unvaccinated children and adolescents aged 6 months to 19 years from eight Canadian provinces and territories were invited to participate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!